Clinical Trial Update: AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA [Phase 2]

View source ↗

Summary

A Phase II single-arm trial evaluating durvalumab in combination with platinum-etoposide chemotherapy as first-line treatment for extensive-stage extrapulmonary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrapulmonary Small Cell Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Durvalumab (durvalumab)
• Etoposide (Etoposide)

Snippet

Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica | Conditions: Extrapulmonary Small Cell Carcinoma | Phase 2 | Status: RECRUITING